Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

<pre id="mfknv"><strike id="mfknv"><input id="mfknv"></input></strike></pre>

<abbr id="mfknv"></abbr>

You are here: Industry Insights > AZD7442

News List

AZ kicks off PhI trial of potential COVID-19 therapy pharmatimes
August 26, 2020
AstraZeneca has dosed the first participants in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) being developed for prevention and treatment of COVID-19.

Previous page 1 2 3 Next page

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號(hào)-182 滬公網(wǎng)安備31010402010101號(hào)
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service

<li id="yhkoa"><acronym id="yhkoa"></acronym></li>

<style id="yhkoa"></style>